Zimmer Launches New Medical Education and BioSkills Training Program
The Zimmer Institute Redefines Industry-driven Training
WARSAW, Ind., July 27 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) today announced the launch of the new Zimmer Institute. Over the past year, Zimmer has collaborated with teaching surgeons and subject matter experts to develop a unique model for surgeon and clinician training. Combining its Medical Education, BioSkills Training and Surgeon-to-Surgeon programs under one, consolidated service offering, the enhanced Zimmer Institute provides a highly interactive environment for surgeon and clinician education that the Company believes sets new standards for the industry.
A continuum of courses is available through the Zimmer Institute, spanning online learning modules, interactive small group discussions, intensive case study reviews, hands-on cadaver-based training and surgeon-to-surgeon training programs. Course modules have been tailored to match an individual surgeon's experience level, providing in-depth knowledge on products and procedures. Zimmer Institute courses have a high faculty-to-student ratio and incorporate new technologies, promoting greater interaction with faculty trainers and participant collaboration. Courses are offered at many regional locations worldwide, minimizing the time participants will have to spend away from their practices.
"Advanced professional training is in great demand and our ability to meet this need is vital to supporting our customers," noted Audrey Beckman, Senior Vice President, Zimmer Institute. "We recognize the importance of being at the forefront of professional education and are committed to providing medical and dental professionals with unparalleled training and course offerings that will not only teach them how to use our products safely and effectively, but will also give them the opportunity to hone and refine their surgical skill sets."
Courses conducted using the new format have been underway since 2008, and are being rolled out globally, with more than 800 events scheduled in 2009, training more than 12,000 medical professionals and more than 8,000 dental professionals. Additional information regarding the enhanced Zimmer Institute is available at zimmerinstitute.zimmer.com.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2008 sales were approximately $4.1 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
For more information about Zimmer, visit www.zimmer.com
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Corporate Integrity Agreement through 2012; the impact of our enhanced healthcare compliance global initiatives and business practices on our relationships with customers and consultants, our market share and our overall financial performance; the success of our quality initiatives; the outcome of the informal investigation by the U.S. Securities and Exchange Commission into Foreign Corrupt Practices Act matters announced in October 2007; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks; the impact of temporarily suspending U.S. distribution of one of our key hip replacement products; product liability and intellectual property litigation losses; reductions in reimbursement levels from third-party payors and cost-containment efforts of healthcare purchasing organizations; our ability to retain the independent agents and distributors who market our products; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the costs of defending or resolving putative class action securities litigation and lawsuits, investigations or other proceedings resulting from our September 2007 settlement with the U.S. government and other matters. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
SOURCE Zimmer Holdings, Inc.
WARSAW, Ind., July 27 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) today announced the launch of the new Zimmer Institute. Over the past year, Zimmer has collaborated with teaching surgeons and subject matter experts to develop a unique model for surgeon and clinician training. Combining its Medical Education, BioSkills Training and Surgeon-to-Surgeon programs under one, consolidated service offering, the enhanced Zimmer Institute provides a highly interactive environment for surgeon and clinician education that the Company believes sets new standards for the industry.
A continuum of courses is available through the Zimmer Institute, spanning online learning modules, interactive small group discussions, intensive case study reviews, hands-on cadaver-based training and surgeon-to-surgeon training programs. Course modules have been tailored to match an individual surgeon's experience level, providing in-depth knowledge on products and procedures. Zimmer Institute courses have a high faculty-to-student ratio and incorporate new technologies, promoting greater interaction with faculty trainers and participant collaboration. Courses are offered at many regional locations worldwide, minimizing the time participants will have to spend away from their practices.
"Advanced professional training is in great demand and our ability to meet this need is vital to supporting our customers," noted Audrey Beckman, Senior Vice President, Zimmer Institute. "We recognize the importance of being at the forefront of professional education and are committed to providing medical and dental professionals with unparalleled training and course offerings that will not only teach them how to use our products safely and effectively, but will also give them the opportunity to hone and refine their surgical skill sets."
Courses conducted using the new format have been underway since 2008, and are being rolled out globally, with more than 800 events scheduled in 2009, training more than 12,000 medical professionals and more than 8,000 dental professionals. Additional information regarding the enhanced Zimmer Institute is available at zimmerinstitute.zimmer.com.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2008 sales were approximately $4.1 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
For more information about Zimmer, visit www.zimmer.com
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Corporate Integrity Agreement through 2012; the impact of our enhanced healthcare compliance global initiatives and business practices on our relationships with customers and consultants, our market share and our overall financial performance; the success of our quality initiatives; the outcome of the informal investigation by the U.S. Securities and Exchange Commission into Foreign Corrupt Practices Act matters announced in October 2007; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks; the impact of temporarily suspending U.S. distribution of one of our key hip replacement products; product liability and intellectual property litigation losses; reductions in reimbursement levels from third-party payors and cost-containment efforts of healthcare purchasing organizations; our ability to retain the independent agents and distributors who market our products; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the costs of defending or resolving putative class action securities litigation and lawsuits, investigations or other proceedings resulting from our September 2007 settlement with the U.S. government and other matters. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
SOURCE Zimmer Holdings, Inc.
posted by Poonam at
3:26 AM
1 Comments:
"If the recall continues, tomorrow will be dreary for the manufacturer of zimmer hip recall."
By
Anonymous, At
June 28, 2012 at 8:40 PM
Post a Comment
Subscribe to Post Comments [Atom]
<< Home